Exploring New Frontiers in Direct to Patient (DTP) Home Delivery Services for Clinical Trial Materials provides an in-depth look at reasons to consider a DTP solution. Included in the discussion are concerns with the traditional distribution channels, advantages and challenges of a DTP service solution, regulatory considerations when planning a global project, and insight into efficiently collaborating with partnering networks. Leslie joined Marken in 2011 with an extensive background in the life sciences and early drug development. She has led the development of Marken's direct to patient delivery services to support human clinical trials. Leslie earned her PhD in Pharmacology and Toxicology from the University of Mississippi Medical Center, Jackson, MS, and is certified by the American Board of Toxicology. She was employed as a toxicologist and study director for the U.S Army’s Center for Health Promotion and Preventive Medicine, and for Therimmune Research. Prior to joining Marken, she was a leader in business development for GeneLogic, Xceleron, Inc., Harlan Laboratories, and the Battelle Memorial Institute.
Global Director, Preclinical and Direct to Patient Services
- Marken Successfully Delivers Critical Stem Cell Samples to Patients
- Exploring the value of home visits in clinical trials, the benefits gained by both the patient and the sponsor
- Marken Delivers Compassionate Use Dose of Emergency Medication to Critical Pediatric Patient
- Dissolving boundaries in worldwide clinical trial logistics